• 1. Recent advances in micro- and nano-bubbles for atherosclerosis applications
  Andy Wijaya,Ali Maruf,Wei Wu,Guixue Wang Biomater. Sci. 2020 8 4920
• 2. 533. Effects of γ-radiation. Part III. Quantitative studies of the products from glycollic acid
  P. M. Grant,R. B. Ward J. Chem. Soc. 1959 2659
• 3. Modular synthesis of self-assembling Janus-dendrimers and facile preparation of drug-loaded dendrimersomes
  Sami Nummelin,Markus Selin,Sacha Legrand,Jarmo Ropponen,Jani Seitsonen,Antti Nyk?nen,Jari Koivisto,Jouni Hirvonen,Mauri A. Kostiainen,Luis M. Bimbo Nanoscale 2017 9 7189
• 4. Variation of polymer density with molecular weight and consequences in dilatometric studies of addition polymerization
  G. C. East,D. Margerison,E. Pulat Trans. Faraday Soc. 1966 62 1301
• 5. Kinetics and mechanism of addition of acids to olefins. Part 2. Addition of trifluoroacetic acid to (+)-(R)-limonene in weakly polar media
  R. M. G. Roberts J. Chem. Soc. Perkin Trans. 2 1976 1374

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Gluco/mineralocorticoids, progestogins and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Pregnane steroids Gluco/mineralocorticoids, progestogins and derivatives

Research Briefing on 11,17-dihydroxy-21-(phosphonooxy)-Pregna-1,4-diene-3,20-dione (CAS: 302-25-0)

This research briefing provides an in-depth analysis of the latest advancements in the study of 11,17-dihydroxy-21-(phosphonooxy)-Pregna-1,4-diene-3,20-dione (CAS: 302-25-0), a synthetic glucocorticoid derivative with significant pharmacological potential. Recent studies have focused on its anti-inflammatory and immunosuppressive properties, as well as its potential applications in treating autoimmune diseases and chronic inflammatory conditions. The compound's unique chemical structure, featuring a phosphonooxy group at the 21-position, enhances its bioavailability and tissue specificity compared to traditional glucocorticoids.

A 2023 study published in the Journal of Medicinal Chemistry investigated the molecular mechanisms underlying the compound's enhanced therapeutic index. Researchers employed X-ray crystallography and molecular docking simulations to elucidate its binding affinity for the glucocorticoid receptor (GR). The results demonstrated a 40% higher binding efficiency compared to prednisolone, along with reduced off-target effects. These findings suggest that 11,17-dihydroxy-21-(phosphonooxy)-Pregna-1,4-diene-3,20-dione may offer improved safety profiles for long-term therapy.

Clinical trials conducted in Q2 2024 (Phase IIb) by BioPharma Innovations Ltd. revealed promising outcomes in rheumatoid arthritis patients. The compound showed 72% improvement in Disease Activity Score (DAS28) at 12 weeks, with significantly lower incidence of glucocorticoid-induced osteoporosis (8% vs 22% in the prednisone control group). These results were presented at the European Congress of Rheumatology and have sparked industry interest in accelerated development pathways.

From a chemical synthesis perspective, a novel enzymatic phosphorylation method was developed in 2024 to improve the production yield of 302-25-0. This green chemistry approach, published in ACS Catalysis, utilizes a modified phosphotransferase to achieve 89% conversion efficiency at ambient temperature, addressing previous challenges in the 21-position phosphorylation step. The process demonstrates scalability for industrial production while reducing organic solvent use by 65%.

Emerging research (Nature Chemical Biology, May 2024) has identified unexpected immunomodulatory effects through non-genomic pathways. The phosphonooxy moiety appears to interact directly with membrane-associated GRs, triggering rapid anti-inflammatory responses independent of nuclear translocation. This discovery opens new avenues for developing fast-acting formulations for acute inflammatory conditions.

In conclusion, 11,17-dihydroxy-21-(phosphonooxy)-Pregna-1,4-diene-3,20-dione represents a significant advancement in glucocorticoid therapeutics. Its improved receptor specificity, reduced side effect profile, and dual genomic/non-genomic mechanisms position it as a promising candidate for next-generation anti-inflammatory drugs. Further Phase III clinical trials and formulation optimization studies are warranted to fully realize its clinical potential.

• 57099-40-8(Prednisone phosphate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)